Laboratory of Biochemistry and Molecular Biology Research, Fujian Cancer Hospital of Fujian Medical University Teaching Hospital, Fuzhou, Fujian 350014, China.
Int J Clin Oncol. 2010 Aug;15(4):359-68. doi: 10.1007/s10147-010-0067-4. Epub 2010 Apr 1.
Thymidine kinase 1 in serum (STK1) has been found to be a reliable proliferation marker in clinical trials. In this study, we examined the significance of STK1 in routine clinical settings.
The concentration of STK1 was determined by a sensitive dot blot ECL assay. The STK1 value was correlated to clinical stage and reactions and used for monitoring the outcome of surgery and/or multidrug chemotherapy of 1,247 patients with five different types of carcinomas (lung, esophagus, gastric, head and neck, and thyroid) in routine clinical settings.
The STK1 values correlated with the clinical stage in patients with lung, esophagus, thyroid, and gastric carcinomas. After treatment, STK1 declined in all tumor groups after treatments (P < 0.01). The STK1 was low (<2 pM) or decreasing during treatment in patients with clinical reactions of complete response (CR) or partial response (PR), but high (>2 pM) or increasing in patients with stable disease (SD) or progressive disease (PD), some of them showing metastasis. STK1 also reflected the differences in clinical reactions when surgery and chemotherapy were compared.
We concluded that the concentration of TK1 in serum correlates to clinical stages and clinical reactions and monitors the effect of tumor therapies, not only in controlled clinical trials, but also in routine clinical settings.
血清胸苷激酶 1（STK1）已被发现是临床试验中一种可靠的增殖标志物。在这项研究中，我们研究了 STK1 在常规临床环境中的意义。
通过灵敏的斑点印迹 ECL 测定法测定 STK1 的浓度。将 STK1 值与临床分期和反应相关联，并用于监测 1247 例五种不同类型的癌（肺癌、食管癌、胃癌、头颈部癌和甲状腺癌）患者手术和/或多药化疗结果的常规临床环境中。
STK1 值与肺癌、食管癌、甲状腺癌和胃癌患者的临床分期相关。治疗后，所有肿瘤组的 STK1 值均下降（P < 0.01）。在具有完全缓解（CR）或部分缓解（PR）临床反应的患者中，STK1 在治疗过程中降低（<2 pM）或持续降低，但在稳定疾病（SD）或进展性疾病（PD）患者中升高（>2 pM）或升高，其中一些患者出现转移。STK1 还反映了手术和化疗之间临床反应的差异。
我们得出结论，血清 TK1 浓度与临床分期和临床反应相关，并监测肿瘤治疗效果，不仅在对照临床试验中，而且在常规临床环境中也是如此。
